Publications by authors named "Charon Lessing"

Claim this Profile
D
Decision-making on listing new medicines for public funding in New Zealand: the case of 'new' type 2 diabetes medications.
Farzana Sarkisova, Charon Lessing, Caroline Stretton

J Prim Health Care· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Zealand patients' understanding of brand substitution and opinions on copayment options for choice of medicine brand.
Charon Lessing, Toni Ashton, Peter Davis

Aust Health Rev· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Do users of risperidone who switch brands because of generic reference pricing fare better or worse than non-switchers? A New Zealand natural experiment.
Charon Lessing, Toni Ashton, Peter Davis

Adm Policy Ment Health· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Evaluation of Health Service Impacts Consequent to Switching from Brand to Generic Venlafaxine in New Zealand under Conditions of Price Neutrality.
Charon Lessing, Toni Ashton, Peter Davis

Value Health· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact on health outcome measures of switching to generic medicines consequent to reference pricing: the case of olanzapine in New Zealand.
Charon Lessing, Toni Ashton, Peter B Davis

J Prim Health Care· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand.
Charon Lessing, Toni Ashton, Peter Davis

Appl Health Econ Health Policy· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The availability, pricing and affordability of three essential asthma medicines in 52 low- and middle-income countries.
Zaheer-Ud-Din Babar, Charon Lessing, Cécile Mace, Karen Bissell

Pharmacoeconomics· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis